Molecular Profiling of Persistent Fever Syndromes

Abstract

Persistent fever syndromes represent a significant diagnostic and therapeutic challenge in clinical practice, often encompassing a broad differential that includes infectious, autoimmune, and neoplastic etiologies. Recent advances in molecular profiling have revolutionized our understanding of these syndromes, allowing for earlier, more precise diagnosis and tailored management strategies. This review synthesizes current evidence on the role of molecular diagnostics in persistent fever syndromes, highlighting epidemiological trends, underlying mechanisms, clinical features, and the impact of recent technological advances on patient care. The discussion integrates guideline recommendations and explores emerging therapies, providing a comprehensive reference for healthcare professionals managing patients with prolonged febrile illnesses.

Introduction

Persistent fever syndromes, defined as fevers lasting longer than three weeks without a clear etiology after initial evaluation, remain a diagnostic dilemma for physicians. These syndromes, often termed fever of unknown origin (FUO), require a systematic approach to evaluation due to their heterogeneous causes. The advent of molecular profiling, including next-generation sequencing (NGS), polymerase chain reaction (PCR)-based assays, and gene expression analyses, has transformed the diagnostic landscape. Molecular tools now facilitate the identification of elusive pathogens, genetic autoinflammatory syndromes, and malignancies, reshaping clinical algorithms and improving patient outcomes. This article reviews the clinical utility and implications of molecular profiling in the approach to persistent fever syndromes, emphasizing evidence-based practice and recent guideline updates.

Epidemiology / Disease Burden

Persistent fever syndromes contribute substantially to morbidity, healthcare utilization, and diagnostic costs worldwide. The incidence of FUO varies by population, estimated at 2–9 cases per 100,000 hospital admissions. Pediatric and adult populations show distinct etiologic patterns, with infections predominating in children and autoimmune or neoplastic causes more common in adults. Global trends have shifted as molecular diagnostics reveal previously unrecognized infectious agents and genetic autoinflammatory disorders. In resource-limited settings, the burden is amplified by limited access to advanced diagnostic modalities, leading to prolonged hospital stays and empirical treatments that may not address the underlying etiology.

Pathophysiology

The pathophysiology of persistent fever syndromes is diverse, reflecting the multiple underlying processes that can drive sustained pyrexia. Infectious etiologies may involve persistent or occult pathogens evading detection by conventional methods. Autoinflammatory syndromes, such as familial Mediterranean fever or adult-onset Still's disease, result from genetic mutations affecting innate immune regulation, leading to dysregulated cytokine release and chronic systemic inflammation. Neoplastic causes, including lymphoproliferative disorders, may trigger fever through cytokine production or paraneoplastic phenomena. Molecular profiling enables identification of specific genetic mutations, aberrant signaling pathways, and pathogen-specific nucleic acids, providing mechanistic insights and diagnostic precision.

Risk Factors

Risk factors for persistent fever syndromes are multifactorial and depend on the underlying etiology. Immunocompromised states, such as HIV infection, chemotherapy, or chronic corticosteroid use, predispose to atypical or opportunistic infections that may manifest as prolonged fever. Genetic predisposition plays a critical role in monogenic autoinflammatory syndromes, with identifiable mutations in MEFV, NLRP3, and other genes. Epidemiological factors, including travel history, exposure to endemic pathogens, and family history of autoimmune or autoinflammatory diseases, can guide the diagnostic approach. Molecular profiling assists in identifying high-risk individuals and stratifying patients based on genetic and pathogen-specific risk factors.

Clinical Features

The clinical presentation of persistent fever syndromes varies widely, often overlapping across infectious, autoimmune, and neoplastic categories. Common features include recurrent or sustained fever, malaise, weight loss, and night sweats. Organ-specific symptoms, such as rash, arthralgia, lymphadenopathy, or hepatosplenomegaly, may provide diagnostic clues. In genetic autoinflammatory syndromes, periodic fever episodes are often accompanied by serositis, arthritis, or skin manifestations. Detailed history, including travel, exposure, and family background, is crucial. Molecular diagnostics can sometimes reveal subclinical or atypical presentations by detecting pathogen DNA/RNA or disease-associated mutations, even in the absence of classic symptoms.

Diagnosis

The diagnostic approach to persistent fever syndromes integrates clinical, laboratory, imaging, and molecular modalities. Initial evaluation includes comprehensive history, physical examination, and basic laboratory tests (CBC, ESR/CRP, cultures, imaging). When conventional workup is inconclusive, molecular profiling becomes invaluable. PCR and NGS can detect rare or fastidious pathogens from blood, tissue, or body fluids. Genetic testing identifies monogenic autoinflammatory syndromes, guiding targeted therapy. Gene expression profiling and somatic mutation analysis may differentiate between neoplastic and inflammatory processes. The use of multiplex panels and metagenomic sequencing enables comprehensive pathogen detection, reducing diagnostic delay and informing management.

Treatment & Management

Management of persistent fever syndromes is guided by the identified etiology. Targeted antimicrobial therapy is preferred for infectious causes, while immunosuppressive or biologic agents are indicated for autoimmune and autoinflammatory conditions. In cases of malignancy-associated fever, oncologic management takes precedence. Molecular profiling informs therapeutic decisions by identifying actionable mutations, resistance markers, or specific pathogens. Empirical therapy may be necessary in critically ill patients, but molecular diagnostics facilitate early de-escalation or modification of treatment. Multidisciplinary care, involving infectious disease specialists, rheumatologists, geneticists, and oncologists, is often required for optimal outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable advances in molecular techniques for persistent fever syndromes. Metagenomic NGS enables unbiased pathogen discovery, leading to the identification of novel or unexpected agents. Whole exome and genome sequencing have expanded the spectrum of recognized monogenic autoinflammatory syndromes, allowing for individualized therapy. Biomarker discovery, including cytokine signatures and transcriptomic profiles, offers potential for prognostic stratification and therapy monitoring. Emerging therapies, such as targeted biologics (e.g., IL-1 or IL-6 inhibitors) and small-molecule inhibitors, are guided by molecular insights into disease mechanisms. Integration of molecular diagnostics into routine practice is redefining the standard of care for patients with prolonged febrile illnesses.

Guideline Recommendations

Recent guidelines from leading societies, including the Infectious Diseases Society of America and the European League Against Rheumatism, advocate for a stepwise, evidence-based approach to persistent fever syndromes. Molecular profiling is recommended when conventional workup fails to yield a diagnosis or when rare or atypical pathogens are suspected. Genetic testing is advised for patients with recurrent or familial fever syndromes, particularly in pediatric populations. Guidelines emphasize the importance of multidisciplinary evaluation, judicious use of empirical therapy, and the integration of molecular findings into clinical decision-making. The ongoing evolution of molecular technologies necessitates regular updates to guideline recommendations.

Conclusion

Molecular profiling has redefined the diagnostic and therapeutic landscape of persistent fever syndromes, enabling precise identification of etiologies that elude conventional modalities. These advances enhance early diagnosis, inform targeted treatment, and improve patient outcomes. Continued integration of molecular diagnostics, coupled with adherence to evidence-based guidelines and interdisciplinary collaboration, is essential for optimizing care in this complex clinical domain. Ongoing research and technological innovation hold promise for further improving diagnostic yield and expanding therapeutic options for patients with persistent fever syndromes.